Relay Therapeutics Valuation
| RLAY Stock | USD 6.20 0.06 0.98% |
At this time, the company appears to be undervalued. Relay Therapeutics holds a recent Real Value of $10.6 per share. The prevailing price of the company is $6.2. Our model determines the value of Relay Therapeutics from analyzing the company fundamentals such as Current Valuation of 247.98 M, return on equity of -0.43, and Shares Owned By Insiders of 1.71 % as well as examining its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Relay Therapeutics' valuation include:
Price Book 1.4894 | Enterprise Value 248 M | Enterprise Value Ebitda (0.80) | Price Sales 28.8395 | Enterprise Value Revenue 10.7381 |
Undervalued
Today
Please note that Relay Therapeutics' price fluctuation is moderately volatile at this time. Calculation of the real value of Relay Therapeutics is based on 3 months time horizon. Increasing Relay Therapeutics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Relay Therapeutics is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Relay Stock. However, Relay Therapeutics' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 6.2 | Real 10.6 | Target 24.22 | Hype 6.13 | Naive 5.97 |
The intrinsic value of Relay Therapeutics' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Relay Therapeutics' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Relay Therapeutics helps investors to forecast how Relay stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Relay Therapeutics more accurately as focusing exclusively on Relay Therapeutics' fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Relay Therapeutics' intrinsic value based on its ongoing forecasts of Relay Therapeutics' financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Relay Therapeutics' closest peers.
Relay Therapeutics Cash |
|
Relay Valuation Trend
Analysing the historical paterns of Relay Therapeutics' enterprise value and its market capitalization is a good way to estimate and gauge the value of Relay Therapeutics over time and is usually enough for investors to make rational market timing decisions.
Relay Therapeutics Total Value Analysis
Relay Therapeutics is at this time forecasted to have valuation of 247.98 M with market capitalization of 1.04 B, debt of 53.47 M, and cash on hands of 1.05 B. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Relay Therapeutics fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
247.98 M | 1.04 B | 53.47 M | 1.05 B |
Relay Therapeutics Investor Information
About 79.0% of the company shares are owned by institutional investors. The company has price-to-book ratio of 1.49. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Relay Therapeutics has Price/Earnings To Growth (PEG) ratio of 0.07. The entity recorded a loss per share of 2.61. The firm had not issued any dividends in recent years. Based on the key indicators related to Relay Therapeutics' liquidity, profitability, solvency, and operating efficiency, Relay Therapeutics is not in a good financial situation at this time. It has a very high odds of going through financial crisis in December.Relay Therapeutics Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Relay Therapeutics has an asset utilization ratio of 3.03 percent. This suggests that the Company is making $0.0303 for each dollar of assets. An increasing asset utilization means that Relay Therapeutics is more efficient with each dollar of assets it utilizes for everyday operations.Relay Therapeutics Ownership Allocation
Relay Therapeutics owns a total of 167.38 Million outstanding shares. The majority of Relay Therapeutics outstanding shares are owned by third-party entities. These institutional holders are usually referred to as non-private investors looking to secure positions in Relay Therapeutics to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Relay Therapeutics. Please pay attention to any change in the institutional holdings of Relay Therapeutics as this could imply that something significant has changed or is about to change at the company. Please note that no matter how many assets the company maintains, if the real value of the company is less than the current market value, you may not be able to make money on it.Relay Therapeutics Profitability Analysis
The company reported the previous year's revenue of 25.55 M. Net Loss for the year was (341.97 M) with profit before overhead, payroll, taxes, and interest of 1.38 M.About Relay Therapeutics Valuation
Our relative valuation model uses a comparative analysis of Relay Therapeutics. We calculate exposure to Relay Therapeutics's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Relay Therapeutics's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | 20.3 M | 14.9 M | |
| Pretax Profit Margin | (13.39) | (14.06) | |
| Operating Profit Margin | (14.60) | (15.33) | |
| Net Loss | (13.39) | (14.06) | |
| Gross Profit Margin | 0.79 | 0.83 |
Relay Therapeutics Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.
| Common Stock Shares Outstanding | 122.6 M |
Relay Therapeutics Current Valuation Indicators
Valuation refers to the process of determining the present value of Relay Therapeutics and all of its assets. It can be calculated using a number of techniques. As many analysts who try to value Relay we look at many different elements of the entity such as Relay's management, its prospective future earnings, the current market value of the company's assets, as well as its capital structure formation.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Relay Therapeutics, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Relay Therapeutics' valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Relay Therapeutics' worth.Additional Tools for Relay Stock Analysis
When running Relay Therapeutics' price analysis, check to measure Relay Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Relay Therapeutics is operating at the current time. Most of Relay Therapeutics' value examination focuses on studying past and present price action to predict the probability of Relay Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Relay Therapeutics' price. Additionally, you may evaluate how the addition of Relay Therapeutics to your portfolios can decrease your overall portfolio volatility.